Redcliffe Labs expands in South India with acquisition of Celara Diagnostics

New partnership enhances diagnostic services, bringing advanced radiology and pathology expertise to Karnataka

0
65
New Delhi: Redcliffe Labs has announced the acquisition of Celara Diagnostics, a well-established diagnostics chain in Bengaluru. This marks a significant expansion for Redcliffe in South India, aiming to enhance its radiology and pathology services.
Celara Diagnostics is renowned for its advanced diagnostic facilities, including high-end radiology and pathology services, with two state-of-the-art centers located in Basavanagudi and Shivaji Nagar. The integration of Celara Diagnostics into Redcliffe Labs’ extensive network will broaden the range of diagnostic services available to patients in Karnataka, offering high-quality radiology and specialized pathology with improved turnaround times and an enhanced customer experience.
The acquisition also brings onboard seasoned professionals Dr. Radhesh S. and Dr. Rekha Radhesh, who together boast over 35 years of experience in diagnostic medicine. Dr. Radhesh, the founder of the Clumax diagnostics chain, is known for conducting over 150,000 MRI scans and 100,000 CT scans, while Dr. Rekha Radhesh is a distinguished pathologist committed to maintaining high standards of diagnostic accuracy.
Aditya Kandoi, Founder & CEO of Redcliffe Labs, emphasized, “Our commitment to quality diagnostics has driven us to expand our presence in South India through the strategic acquisition of Celara Diagnostics. This strategic partnership strengthens our ability to deliver conclusive, precision-driven results that empower healthcare providers across the region. We look forward to leveraging Dr. Radhesh’s and Dr. Rekha’s extensive experience to drive innovation and set new standards in diagnostic care.”
Dr. Radhesh S. shared his enthusiasm for the new partnership, stating, “As healthcare professionals, our foremost commitment is to the well-being of our patients. Our integration with Redcliffe Labs marks an exciting new chapter in our mission to deliver exceptional care. This partnership will undoubtedly enhance our ability to provide precise, timely, and comprehensive diagnostics, ultimately leading to better health outcomes for our community.”
With this acquisition, Redcliffe Labs aims to set new benchmarks for clinical excellence and accessibility, reinforcing its mission to provide quality diagnostics across India. The labs will now offer over 3,600 routine and specialized tests, including advanced capabilities in biochemistry, hematology, immunoassays, histopathology, clinical pathology, cytopathology, molecular and genomic testing, hormones, microbiology, and infectious disease serology.